指南与共识类风湿关节炎

合成与生物DMARDs安全性:为2025年EULAR类风湿关节炎管理建议更新提供的系统文献综述

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritis.
指南 / 共识 · Ann Rheum Dis · 2026-04-08

该系统文献综述检索2022年1月14日至2025年1月22日发表的观察性研究与随机对照试验,评估csDMARDs、bDMARDs、tsDMARDs及糖皮质激素的安全性,最终纳入71篇文献。感染是最常评估的结局,bDMARDs的严重感染多于csDMARDs,JAKi的带状疱疹风险高于bDMARDs,JAKi的静脉血栓栓塞风险似升高而主要不良心血管事件风险未见一致增加。该综述与疗效综述共同为2025年EULAR类风湿关节炎管理建议更新提供依据。

要点

  • bDMARDs严重感染风险高于csDMARDs,JAKi带状疱疹风险高于bDMARDs。
  • JAKi相比bDMARDs静脉血栓栓塞风险似升高,主要归因于肺栓塞。
  • 未发现JAKi相比bDMARDs主要不良心血管事件风险一致升高的证据。

核心结论

  • 评估安全性结局的研究明显增多,多为观察性研究,主要关注恶性肿瘤、血栓栓塞和心血管事件,且多数研究涉及JAKi安全性。
  • 该综述与DMARDs疗效综述共同为2025年EULAR类风湿关节炎管理建议更新提供依据。

研究设计与样本

  • 系统文献综述,检索Medline、Embase、Cochrane CENTRAL和Web of Science,纳入2022年1月14日至2025年1月22日发表的以DMARD安全性为主要终点的观察性研究和随机对照试验。
  • 另对DMARD监测进行单独检索,检索时间自数据库建库至2025年1月22日。
  • 纳入研究需设对照组,共识别3837篇文献,321篇进入全文审查,最终纳入71篇。

主要发现

  • 感染是最常评估的结局:13项研究考察严重或住院感染(通常为细菌、机会性和带状疱疹感染的复合终点),1项涉及非严重感染。
  • bDMARDs的严重感染比csDMARDs更常见;JAKi的带状疱疹风险高于bDMARDs。
  • JAKi相比bDMARDs未增加结核风险,但英夫利西单抗和阿达木单抗的结核风险高于依那西普。
  • 20项研究报告心血管和血栓栓塞事件;未发现JAKi相比bDMARDs主要不良心血管事件风险一致升高的证据;JAKi相比bDMARDs静脉血栓栓塞风险似升高,主要归因于肺栓塞。

关键数值与推荐

  • JAKi相比bDMARDs:带状疱疹风险更高,结核风险未增加,静脉血栓栓塞风险似升高(主要归因于肺栓塞),主要不良心血管事件风险未见一致升高。
  • 英夫利西单抗和阿达木单抗相比依那西普:结核风险更高。
  • RA患者使用DMARDs相比一般人群:NMSC增加,与特定DMARD无关。
  • 14项研究报告药物留存和不良事件相关停药,8项评估其他特定不良事件,胃肠道穿孔和脱髓鞘疾病各在3项研究中报告。
  • DMARD监测检索未识别到符合条件的文献。

临床怎么用

  • 在RA管理中权衡bDMARDs与csDMARDs的严重感染风险,使用JAKi时关注带状疱疹和静脉血栓栓塞(尤其肺栓塞)风险。
  • 选择英夫利西单抗或阿达木单抗时考虑结核风险高于依那西普,JAKi未显示结核风险增加。
  • 对使用DMARDs的RA患者关注NMSC风险,该风险与特定DMARD无关。

局限性

  • 本综述中相当比例的研究依赖索赔数据库评估安全性结局,这对安全性研究存在重要的方法学局限性。
  • 过去3年探讨糖皮质激素安全性结局的研究不多。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aims to perform a systematic literature review (SLR) concerning the safety of synthetic and biological disease-modifying antirheumatic drugs (DMARDs) for the 2025 update of European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of rheumatoid arthritis (RA). METHODS: Medline, Embase, Cochrane CENTRAL, and Web of Science were searched for observational and randomised controlled trials with a primary endpoint of DMARD safety on the conventional synthetic (cs-), biological (b-), and targeted synthetic-DMARDs, as well as glucocorticoids, published between January 14, 2022, and January 22, 2025. Separate searches on DMARD monitoring were conducted from database inception to January 22, 2025. A comparator group was required for inclusion. All safety outcomes were included. RESULTS: A total of 3837 articles were identified, with 321 selected for full-text review; 71 articles were included. Across the evidence base, infections were the most frequently assessed outcome: 13 studies examined serious or hospitalised infections, usually as composite endpoints of bacterial, opportunistic, and herpes zoster infection, while 1 addressed nonserious infections. Serious infections were more common with bDMARDs than csDMARDs. Janus kinase inhibitors (JAKis) showed a higher herpes zoster risk than bDMARDs. Tuberculosis risk was not increased with JAKis compared with bDMARDs, but was higher with infliximab and adalimumab compared with etanercept. Fifteen studies evaluated malignancy, split evenly between analyses of any malignancy and those excluding nonmelanoma skin cancer (NMSC); 2 focused on melanoma and 2 on NMSC. Increased NMSC was noted in patients with RA using DMARDs compared with the general population, with no link to a specific DMARD. Cardiovascular and thromboembolic events were reported in 20 studies. No consistent evidence of increased major adverse cardiovascular events risk with JAKis compared with bDMARDs was identified. Venous thromboembolism risk appeared elevated with JAKis compared with bDMARDs, driven mainly by pulmonary embolism. Fourteen studies reported retention and adverse event-related withdrawals, and 8 assessed other specific adverse events. Gastrointestinal perforation and demyelinating disease were each reported in 3 studies. No eligible articles were identified in searches on DMARD monitoring. CONCLUSIONS: There has been a notable increase in studies evaluating safety outcomes, with the majority of these being observational studies focusing primarily on malignancy, thromboembolic, and cardiovascular events, with most studies pertaining to JAKi safety. A substantial proportion of studies in this SLR relied on claims databases to evaluate safety outcomes, a practice that carries important methodological limitations for safety research. Surprisingly, not many studies looked into glucocorticoid safety outcomes over the past 3 years. This SLR, along with the SLR on efficacy of DMARDs, informed the 2025 update of the EULAR recommendations for management of RA with synthetic and biological DMARDs.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Laskou F, Konzett V, Smolen JS, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2026. PMID: 41951459. doi:10.1016/j.ard.2026.02.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。